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Dietary sodium restriction has been shown to enhance the
short-term response of blood pressure and albuminuria to
angiotensin receptor blockers (ARBs). Whether this also
enhances the long-term renal and cardiovascular protective
effects of ARBs is unknown. Here we conducted a post-hoc
analysis of the RENAAL and IDNT trials to test this in patients
with type 2 diabetic nephropathy randomized to ARB or
non-renin–angiotensin–aldosterone system (non-RAASi)–based
antihypertensive therapy. Treatment effects on renal and
cardiovascular outcomes were compared in subgroups based
on dietary sodium intake during treatment, measured as the
24-h urinary sodium/creatinine ratio of 1177 patients with
available 24-h urinary sodium measurements. ARB compared
to non-RAASi–based therapy produced the greatest long-term
effects on renal and cardiovascular events in the lowest
tertile of sodium intake. Compared to non-RAASi, the trend in
risk for renal events was significantly reduced by 43%, not
changed, or increased by 37% for each tertile of increased
sodium intake, respectively. The trend for cardiovascular
events was significantly reduced by 37%, increased by 2%
and 25%, respectively. Thus, treatment effects of ARB compared
with non-RAASi–based therapy on renal and cardiovascular
outcomes were greater in patients with type 2 diabetic
nephropathy with lower than higher dietary sodium intake.
This underscores the avoidance of excessive sodium intake,
particularly in type 2 diabetic patients receiving ARB therapy.
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Agents intervening in the renin–angiotensin–aldosterone system
(RAASi) are considered a mainstay of therapy in the preven-
ion of end-stage renal and cardiovascular disease in patients
with diabetes, both in early and late stage of disease.1–4 Despite
proven efficacy of RAASi, it is known that the risk of renal
and cardiovascular disease remains high in a substantial number
of patients.5 The high risk of renal and cardiovascular disease
is closely linked to high residual blood pressure and albuminuria.
To address this high residual risk, further reduction of blood
pressure and albuminuria may be required. One of the
options is to optimize the efficacy of RAASi.
Several studies have consistently demonstrated that dietary
sodium restriction enhances the blood pressure and albumin-
uria response to angiotensin receptor blockers (ARBs) in
both diabetic and nondiabetic patients with chronic kidney
disease.6,7 However, these studies were short in duration and
did not assess whether dietary sodium restriction potentiates
the long-term effects of ARBs on hard renal or cardiovascular
outcomes. In fact, some claim that dietary sodium restriction
by itself may enhance the long-term risk for renal and/or
cardiovascular disease in diabetic patients.8
The purpose of the present study was to determine whether
a low-sodium diet, as indicated by low urinary sodium
excretion, increases the efficacy of an ARB on hard renal and
cardiovascular end points in type 2 diabetic patients with
nephropathy. To this end, data of the Reduction of Endpoints
in NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT)
trials were merged and analyzed.
RESULTS
Characteristics of the study population
Table 1 shows the characteristics of the overall population
and by tertiles of sodium/creatinine ratio. Participants
included in the current report share the characteristics of
the overall RENAAL and IDNT population.1,2 Mean 24-h
sodium/creatinine ratio was 142 (±69) mmol/g and mean
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urinary sodium excretion was 181 (±86) mmol/24 h.
Participants in the upper tertile of 24-h sodium/creatinine
ratio were more likely to be women, less likely to be of black
ethnicity, had a higher 24-h urinary albumin/creatinine ratio,
and a slightly but statistically significantly lower estimated
glomerular filtration rate (eGFR) and hemoglobin level
(Table 1).
Effects of angiotensin receptor blockade on albuminuria
and blood pressure by urinary sodium/creatinine ratio
ARB treatment compared with non-RAASi–based antihyper-
tensive therapy produced the greatest effects on albuminuria
and systolic blood pressure in participants in the lowest tertile of
24-h urinary sodium/creatinine ratio (Table 2). Similar results
were observed when the population was stratified according
to another measure of sodium intake, namely 24-h urinary
sodium excretion (Supplementary Table S1 online).
Relationship between urinary sodium/creatinine ratio
and renal and cardiovascular events
A total of 372 subjects experienced a renal event and 392
subjects experienced a cardiovascular event during follow-up.
Figure 1 shows the Kaplan–Meier survival estimates for renal
and cardiovascular events in subjects treated with ARB and
non-RAASi–based therapy by tertiles of 24-h sodium/
creatinine ratio. Sodium/creatinine ratio did not determine
the renal or cardiovascular outcome of subjects in the non-
RAASi–based therapy group. In ARB-treated subjects, how-
ever, renal and cardiovascular events decreased across
decreasing tertiles of 24-h sodium/creatinine ratio.
Table 1 | Characteristics of the overall population and stratified according to tertiles of 24-h urinary sodium/creatinine ratio
Variable Overall
Stratified by sodium/creatinine ratio
Tertiles 1 2 3
Sodium intake rangea o121 121–153 X153
N 1177 392 393 392
ARB assigned treatment, N 499 173 175 151
Age (years) 59 (8) 59 (8.0) 60 (7.8) 59 (8.0)
Gender (n, % female) 408 (34.7) 82 (20.9) 142 (36.1) 182 (46.9)b
Race (n, %)
White 579 (49.2) 168 (42.8) 197 (50.1) 214 (54.6)b
Black 293 (24.9) 145 (37.0) 98 (24.9) 50 (12.8)b
Hispanic 240 (20.4) 62 (15.8) 76 (19.3) 102 (26.0)b
Asian 46 (3.9) 13 (3.3) 14 (3.6) 19 (4.9)
Others 19 (1.6) 4 (1.0) 8 (2.0) 7 (1.8)
Systolic BP (mmHg) 154.9 (21) 153.1 (21) 155.7 (20) 156.0 (21)
Diastolic BP (mmHg) 83.6 (11) 84.2 (12) 83.2 (11) 83.4 (11)
Serum creatinine (mg/dl) 1.8 (0.5) 1.9 (0.5) 1.8 (0.5) 1.8 (0.6)
eGFR (ml/min per 1.73m2) 44.0 (16) 45.6 (16.7) 44.1 (15.3) 42.2 (16.5)b
HbA1c (%) 8.5 (1.7) 8.4 (1.6) 8.4 (1.6) 8.8 (1.8)
Hemoglobin (mg/dl) 12.5 (2.0) 12.8 (1.9) 12.5 (2.0) 12.4 (1.9)b
Total cholesterol (mg/dl) 225 (57) 210 (57) 222 (52) 232 (59)
Serum albumin (mg/dl) 3.8 (0.5) 3.8 (0.4) 3.8 (0.5) 3.7 (0.5)
Body weight (kg) 89.0 (22) 91.9 (21) 89.8 (23) 85.4 (23)b
Body mass index (kg/m2) 31.2 (6.7) 31.0 (6.3) 31.6 (6.9) 30.9 (6.9)
Urinary albumin excretion (mg/24 h) 1897 (942–3815) 1824 (901–3806) 1765 (947–3450) 2251 (963–3929)
Urinary creatinine excretion (g/24 h) 1.4 (0.6) 1.6 (0.6) 1.4 (0.6) 1.2 (0.4)b
Urinary albumin/creatinine ratio (mg/g) 1554 (775–2946) 1173 (639–2617) 1533 (783–2656) 1905b (910–3675)
Urinary sodium excretion (mmol/24-h) 181 (86) 152 (76) 179 (82) 209 (90)
Urinary sodium/creatinine ratio (mmol/g; based on 24-h) 142 (69) 99 (34) 134 (39) 192 (85)b
Urinary urea excretion (g/24-h)c 9.8 (4.0) 10.3 (4.1) 9.6 (3.9) 9.4 (4.0)
Diuretic use (n, %) 720 (61) 233 (59.4) 225 (57.3) 262 (66.8)
b-Blocker use (n, %) 190 (16) 67 (17.1) 60 (15.3) 63 (16.1)
Calcium antagonist use (n, %) 683 (58) 226 (57.7) 233 (59.3) 224 (57.1)
Abbreviations: ARB, angiotensin receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate.
aRanges are indicated for 24-h sodium/creatinine ratio (mmol/g).
bPo0.05 for tests for trends across urinary/sodium excretion tertiles.
cData are provided from subjects participating in the IDNT trial in whom urinary urea excretion was measured.
Values are expressed as mean with standard deviation. Urinary albumin excretion and urinary albumin/creatinine ratio is expressed as median with interquartile ranges.
Table 2 | Albumin/creatinine ratio and systolic blood pressure
response to ARB therapy compared with non-RAASi-based
therapy at month 6 according to tertiles of 24-h urinary
sodium/creatinine ratio
6-Month response
(95% confidence interval)
24-h Urinary sodium/
creatinine ratio (mmol/g)
24-h ACR response
(%)
Systolic BP response
(mmHg)
o121 44 (55 to 30) 5.0 (8.8 to 1.1)
121–153 16 (32 to +3) 4.6 (8.3 to 1.0)
X153 21 (35 to 2) 3.5 (7.4 to +0.4)
Abbreviations: ACR, albumin to creatinine ratio; ARB, angiotensin receptor blocker;
BP, blood pressure; non-RAASi, non-renin–angiotensin–aldosterone system.
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Effects of angiotensin receptor blockade on renal and
cardiovascular events by urinary sodium/creatinine ratio
Compared with non-RAASi–based therapy, treatment with
ARBs resulted in greater relative effects on renal and
cardiovascular events in subjects in the lowest tertile of
24-h sodium/creatinine ratio (P-value for trend o0.001 for
renal events and 0.021 for cardiovascular events; Figure 2). A
trend toward greater relative risk reductions for hospitaliza-
tion for heart failure events was observed in participants in
the lowest tertile of 24-h sodium/creatinine ratio (Figure 2).
An analysis that stratified the population according to 24-h
urinary sodium excretion provided nearly identical results:
the relative risk reductions for renal events in the lowest vs.
highest tertile of 24-h urinary sodium excretion were 25%
(hazard ratio (HR): 0.75, 95% confidence interval (CI):
0.53–1.05) vs. 27% (HR: 1.27, 95% CI: 0.86–1.88) and for
cardiovascular events 10% (HR: 0.90, 95% CI: 0.65–1.22) vs.
3% (HR: 1.03, 95% CI: 0.73–1.46). An additional analysis
that excluded amlodipine-assigned patients in the IDNT trial
provided comparable results (Supplementary Figure S1
online). Similarly, the results were not different from the
main analyses when irbesartan was compared with amlodi-
pine in the IDNT trial (Supplementary Figure S2 online). A
sensitivity analyses stratifying the population for baseline
24-h sodium/creatinine ratio showed the same trend as the
main analyses with greater ARB treatment effects in subjects
in the lowest tertile of 24-h sodium/creatinine ratio
(Supplementary Table S2 online). Further analyses adjusting
the relative treatment effects for estimated GFR or urinary
urea excertion provided essentially similar results under-
scoring the robustness of the findings.
The effects of ARB treatment on the course of estimated
GFR decline is shown in Figure 3. Participants receiving ARB
therapy in the lowest tertile of 24-h sodium/creatinine ratio
had a significantly slower rate of renal function decline
compared with non-RAASi treatment: 4.4 (95% CI: 3.6–5.1)
vs. 5.7 (5.0–6.4) ml/min per 1.73 m2; P¼ 0.010. No difference
in the rate of eGFR decline was observed between ARB and
non-RAASi–based therapy in the upper two tertiles of 24-h
sodium/creatinine ratio (Figure 3).
DISCUSSION
The results of this study demonstrate that the reductions in
the relative risk of renal and cardiovascular events achieved
with ARB therapy in type 2 diabetic patients with nephrop-
athy are larger in subjects with lower dietary sodium intake
(estimated from 24-h urinary sodium/creatinine ratio). The
renal and cardiovascular protective effects of ARB therapy
compared with non-RAASi–based therapy attenuated in subjects
with larger consumption of sodium so that in subjects with
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Figure 1 |Kaplan–Meier curves according to tertiles of 24-h urinary sodium/creatinine ratio. Kaplan–Meier curves for (a) renal and
(b) cardiovascular events in subjects who received angiotensin receptor blocker (ARB)– and non-renin–angiotensin–aldosterone system
(non-RAASi)–based therapy stratified by tertiles of 24-h sodium/creatinine ratio: o121mmol/g; 121–153mmol/g; X153mmol/g.
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the highest sodium intake the treatment effects on hard renal
and cardiovascular outcomes were completely annihilated.
Treatment guidelines for patients with chronic disease
recommend dietary salt intake of less than 5–6 g per day,
which approximately equals less than 100 mmol of sodium
excretion per day.9,10 Unfortunately, a dietary sodium intake
of 5–6 g per day appears difficult to achieve. In our cohort,
average sodium excretion was 142 mmol per g creatinine or
181 mmol per day, which equals a sodium intake of B11 g
per day, well above the recommended limit. Similar values
were reported in other large intervention trials such as the
REIN I and II cohorts (approximately 170 mmol per day
and 200 mmol per day), and the AASK trial (150 mmol per
day).11–13 Interestingly, the greater treatment effects in subjects
within the lowest tertile of dietary sodium intake were
already observed in subjects with a liberal sodium intake of
99 mmol per g creatinine, equivalent to 152 mmol of sodium
per day, or 8.8 g of salt per day. These data support the
clinical applicability of our findings and underscore global
efforts to avoid excessively high sodium intake.
The data on a direct relationship, irrespective of drug
treatment, between dietary sodium intake and morbidity and
mortality are limited and inconclusive. A Finnish study in the
general population showed that a high salt intake (judged by
urinary sodium excretion) increased the risk of coronary
heart disease mortality, cardiovascular disease mortality, and
all-cause mortality, especially in obese but not in non-obese
individuals.14 These findings were confirmed in the US
general population. Data from the third National Health and
Nutrition Examination Survey demonstrated that each gram
per day increment in sodium intake (estimated from 24-h
dietary recall) was associated with a 20% higher risk for
all-cause mortality.15 In addition, long-term follow-up data
from the Trials of Hypertension Prevention reported that
subjects allocated to the dietary sodium intervention arm
experienced a 25% lower risk on cardiovascular events during
10–15 years of follow-up.16 Another study recently reported
that renal function decline was slower among women with
low than with high dietary sodium intake.17 In contrast,
Ekinci recently reported that lower sodium intake was
independently associated with a higher risk for cardiovascular
and all-cause mortality in individuals with type 2 diabetes.8
However, the population may not be representative for all
type 2 diabetics, as high blood pressure in this population
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Figure 2 | Effect of angiotensin receptor blocker (ARB) treatment vs. non-renin–angiotensin–aldosterone system (non-RAASi)–based
treatment on the risk for renal and cardiovascular outcomes according to tertiles of 24-h urinary sodium/creatinine ratio. The
center of the diamond represents the overall estimate, and the width represents its 95% confidence interval (CI). Solid boxes represent
estimates of treatment effects in subgroups, and the horizontal line represents the 95% CI. ESRD, end-stage renal disease.
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was also paradoxically associated with a decreased risk for
mortality. Nevertheless, another recent population-based cohort
study reported that lower dietary sodium intake (assessed by
single 24-h urine collection) was associated with increased
risk for cardiovascular mortality.18 Our data did not reveal
any association between measures of dietary sodium intake
and renal or cardiovascular outcome in non-RAASi-treated
individuals either in non-adjusted or adjusted analyses. The
varying results on the association between dietary sodium
intake and hard outcomes are probably best explained by the
observational nature of all of these studies, including our
study, and the different methodologies to estimate dietary
sodium intake (i.e., dietary recall as opposed to urinary
sodium excretion and single vs. multiple urinary sodium
measurements). This may have led to unmeasured con-
founding and different effects of various populations with
different dietary patterns. Thus, although various studies
attempt to delineate the relationship between changes in salt
intake and clinical outcomes, they should be interpreted as
hypothesis generating. Randomized controlled trials are needed
to truly assess the impact of salt reduction on morbidity and
mortality.
Far better are the short-term studies on the impact of
restricting dietary sodium intake on blood pressure and
albuminuria responses during RAASi.6,7,19 No long-term
hard outcome data are, however, available on the effects of
RAASi during a low-salt diet in diabetic patients. A recent
post-hoc analysis of the REIN I and II trials in 500 subjects
with nondiabetic nephropathy demonstrated a threefold
larger reduction in the risk of end-stage renal disease during
ramipril therapy in those with low compared with high
urinary sodium excretion.20 However, analyses from the REIN
cohorts solely included patients receiving ramipril. Impor-
tantly, no correction could be made for placebo effects,
rendering it impossible to correct for the fact that there might
be a reason why some people ate more or less salt. By
contrast, in the current study, the effects of ARB treatment on
renal and cardiovascular events were based on non-RAASi–
based controlled comparisons. In addition, the REIN data
can only be applied to individuals with nondiabetic nephrop-
athies. Because of differences in etiology between diabetic
and nondiabetic renal diseases, it is uncertain whether these
findings could be generalized to the broader population of
patients with diabetes. Our study suggests that a liberal
guideline-recommended dietary sodium intake during RAAS
blockade is beneficial for the rapidly growing population of
people with type 2 diabetes and nephropathy. Finally, the
present study suggests for the first time that a lower dietary
sodium intake is associated with larger cardiovascular protec-
tive effects of ARBs.
The enhanced treatment effects on albuminuria and systolic
blood pressure we observed in the lowest tertile of 24-h
sodium/creatinine ratio are indicators of long-term renal and
cardiovascular protection. These effects are in line with
previous studies on the short-term impact of dietary sodium
intake in nondiabetics and diabetics, as also summarized in a
recent Cochrane review,21 and support the interpretation that
a lower dietary sodium intake, rather than other patient
characteristics, potentiate the treatment effects of ARBs.6,19,21
Furthermore, in the lowest tertile of the 24-h sodium/
creatinine ratio, ARB therapy caused an initial decrease in
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eGFR followed by a markedly slower long-term eGFR decline
compared with non-RAASi–based therapy. An initial decrease
in GFR during ARB treatment in combination with a low-
sodium diet has been observed in previous studies as well.7,22
The fall is likely of hemodynamic origin owing to a reduction
in intra-glomerular pressure.23 As an increase in intra-
glomerular pressure is associated with progressive renal function
loss,24 the initial decrease in eGFR can be interpreted as a
sign of the therapeutic effectiveness to achieve long-term
protection.25
Several pathophysiological mechanisms are described that
may explain the blunted treatment effect of ARBs in subjects
with high dietary sodium intake. Experimental and human
studies have shown that a high sodium intake increases
angiotensin-converting enzyme (ACE) activity in renal and
vascular tissues, despite decreased plasma renin and angio-
tensinogen concentrations, which in turn attenuates the effect
of ACE inhibition at a tissue level.26–28 In addition, high
sodium intake exerts direct harmful effects on renal tissues
through activation of transforming growth factor-b.29 More-
over, recent studies support a role of Rac-1, a transducer of
cellular membrane receptor signaling, which can activate the
mineralocorticoid receptor through an aldosterone-indepen-
dent mechanism during high-salt conditions resulting in
renal injury.30 Hence, each of these deleterious effects may
individually, or combined, offset the protective effects of
RAAS inhibition during salt loading. The tendency of less of
an effect or even worsening of renal and cardiovascular
outcome during ARB therapy in the upper dietary sodium
tertile was not statistically significant. However, the point
estimates were compelling enough to warrant further
studies investigating the potential underlying mechanisms,
as well as its clinical relevance for renal and cardiovascular
outcomes.
What could be the implications of our study? Our study
demonstrates that the renal and cardiovascular protective
effects of ARBs are blunted in subjects with type 2 diabetes
and nephropathy in whom dietary sodium intake is
excessively high. This begs for a prospective randomized
controlled trial to definitively prove that restricting dietary
sodium diet as adjunct to RAAS blockade improves renal and
cardiovascular outcomes in chronic kidney disease. Until
further data are available, we advocate avoiding high dietary
sodium intake and recommend adherence to the guideline-
recommended target of salt intake of 5–6 g per day. To achieve
such a change in salt intake, a concert effort of policy makers,
physicians, and patients is required. In this respect, self-
management is an important tool to stimulate patients to
change their dietary sodium intake. Proper education directed
to the individual needs of the patient, self-monitoring of
dietary intake, and engaging social support from relatives
have been shown to be useful to help make and maintain
changes in dietary intake.31
We estimated sodium intake from 24-h sodium excretion.
The use of urinary sodium excretion is a proxy for
sodium intake, but is considered more reliable than food
questionnaires. We used the average sodium excretion during
follow-up for our main analyses, as it is a more accurate
reflection of the actual sodium intake of a patient than
measuring sodium excretion at a single time point. The
results of the sensitivity analyses using only baseline sodium
intake, however, showed a trend similar to our main analyses,
although the P-values for interaction were of borderline
statistical significance. A possible explanation for the
weaker association is that using only baseline urine collec-
tions has led to misclassification and bias. On the other hand,
however, we cannot exclude that reverse causality can lead to
follow-up data showing higher hazard ratios and stronger
associations.
The current report is a retrospective analysis of random-
ized controlled trial data. The results can therefore only be
interpreted as hypothesis generating and not testing. It could
be possible that the differences in patient’s characteristics
across tertiles of dietary sodium intake have contributed to
the enhanced effects of ARBs in the lower tertile of urinary
sodium excretion. However, the greater treatment effects in
patients within the lowest tertile of sodium/creatinine ratio
persisted in various sensitivity analyses such those adjusting
for baseline eGFR, urinary urea excretion, or albuminuria.
Further, similar results were observed in analyses excluding
subjects allocated to calcium channel blocker treatment in the
IDNT trial. We therefore consider it less likely that other
patient characteristics have contributed to the greater renal
and cardioprotective effect during a liberal sodium diet.
Second, 24-hour urinary sodium information was available
for approximately one-third of the overall RENAAL and
IDNT population, which may have influenced the precision
of the estimates of the effect sizes. We estimated sodium
intake from sodium excretion normalized for urinary creatinine
excretion in order to account for collection errors. However,
creatinine excretion also reflects body dimensions, namely
muscle mass, and the normalization for urinary creatinine
excretion is likely to have accounted for the larger proportion
of women and lower proportion of black ethnicity in the
upper tertile of sodium intake. However, the notion that similar
results were observed when the population was stratified
according to 24-h urinary sodium excretion alone, in addition
to the finding that adjustment of the interaction between
treatment and 24-h urinary sodium/creatinine ratio for
gender and race did not alter the findings, indicated the
robustness of the results. Finally, it should be reminded that
the RENAAL and IDNT trials were protocol-driven studies,
and the results can only be applied to patients who share
the characteristics of these populations, i.e., patients with type 2
diabetes, nephropathy, and marked proteinuria.
In conclusion, we demonstrated that the renoprotective
and cardioprotective effect conferred by angiotensin receptor
blockers (losartan or irbesartan) are greater during a con-
comitant lower than higher sodium diet, estimated from 24-h
urinary sodium excretion, in type 2 diabetic patients with
nephropathy. These enhanced effects underline recent calls
for population-wide intervention to reduce dietary salt intake,
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particularly in patients with diabetes and nephropathy treated
with angiotensin receptor blockers.
MATERIALS AND METHODS
Study design
The RENAAL and IDNT trials were two large randomized,
controlled double-blind trials investigating the efficacy of an ARB
(losartan in RENAAL, irbesartan in IDNT) on renal outcomes
compared with placebo (on a background of conventional therapy)
in subjects with type 2 diabetes and nephropathy. In addition, the
IDNT trial included a calcium channel blocker (amlodipine)
treatment arm. The rationale, study design, and outcomes for these
trials have been previously published.32,33 Patients randomized
to study treatment were up-titrated stepwise in two periods of
4 weeks to achieve a blood pressure target of at least 135/85 mm Hg
(50–100 mg losartan (RENAAL), 75–300 mg irbesartan (IDNT), or
2.5–10 mg amlodipine (IDNT)). After the end of the titration
period, the dose of other antihypertensive drugs was increased or
additional antihypertensive agents (but not ACE inhibitors or ARBs
in RENAAL and ACE inhibitors, ARBs, or calcium channel blockers
in IDNT) were added to achieve the target blood pressure.
Study participants
A total of 3228 adult patients with type 2 diabetes and nephropathy
participated in the RENAAL and IDNT trials. Of these participants,
1177 (36%; 591 RENAAL participants and 586 IDNT participants)
collected a 24-h urine, which allowed adequate assessment of daily
sodium excretion rate. These 1177 subjects were included in the
current analysis. Inclusion criteria were similar, but there were
minor differences in detail for these trials. Patients who were eligible
had type 2 diabetes, were aged between 30 and 70 years, and had
serum creatinine levels ranging between 1.3 and 3.0 mg/dl in the
RENAAL trial (with a lower limit of 1.5 mg/dl for males) and 1.0
and 3.0 mg/dl in the IDNT trial (with a lower limit of 1.2 mg/dl for
males). All subjects had proteinuria, defined as 24-h urinary protein
excretion 4500 mg per day in the RENAAL trial and 4900 mg per
day in the IDNT trial. Exclusion criteria for both trials were type 1
diabetes or nondiabetic renal disease.
Follow-up and assessments
After the randomization visit, subjects were seen at 4-week intervals
until 3 months, and subsequently at 3-month intervals. Serum
creatinine and electrolyte levels were measured throughout follow-
up. 24-h Urinary albumin, creatinine, and sodium were measured
at the randomization visit and every 6 months thereafter. The
abbreviated Modification of Diet in Renal Disease equation was used
to estimate GFR.34 Dietary advice during the trial was in keeping
with those of the American Diabetes Association. Treatment effects
were calculated on renal and cardiovascular outcomes according to
tertiles of the mean sodium intake during follow-up. We selected the
mean sodium intake during follow-up as it more accurately reflects
the exposure of a subject to a certain sodium load during the trial
than a single measure. Incontinence and erroneous 24-h urine
collections are typically common in patients with diabetes as a result
of diabetic neuropathy including diabetic bladder dysfunction and
poor bladder emptying.35 To normalize for possible urine collection
errors and body size dimensions, we divided 24-h urinary sodium
excretion by 24-h urinary creatinine excretion.36,37 24-h Albumin-
uria excretion was also normalized for 24-h urinary creatinine
excretion. To establish the robustness of the analyses, we also
performed all analyses according to another measure of sodium
intake, namely 24-h urinary sodium excretion.
Renal and cardiovascular outcomes
The renal outcome in this analysis was defined as a composite of a
confirmed doubling of serum creatinine from baseline or end-stage
renal disease. The latter was defined as the need for chronic dialysis
or renal transplantation. An additional definition for end-stage renal
disease of a serum creatinine X6 mg/dl (X530 mmol/l) applied in
the IDNT trial. The rate of estimated GFR decline over time was an
additional outcome in both trials. The cardiovascular outcome was
the original secondary outcome of both trials defined as the com-
posite of cardiovascular death, myocardial infarction, stroke,
hospitalization for heart failure, or revascularization procedures.
As both the RENAAL and IDNT trial showed that ARB treatment
reduces the rate of hospitalization for heart failure, the interaction
between urinary sodium excretion and ARB treatment was assessed
on this end point as well. All clinical end points were adjudicated by
a blinded end-point committee using rigorous guideline definitions.
Statistics
The effects of ARB treatment vs. non-RAASi–based therapy on renal
and cardiovascular end points were estimated from unadjusted Cox
proportional hazard models. Test for interaction in treatment effects
across tertiles of 24-h urinary sodium/creatinine ratio were
performed by adding interaction terms (ARB treatment assign-
ed*sodium intake) to the relevant Cox models. For subjects who
experienced more than one renal or cardiovascular event during
follow-up, survival time to the first relevant end point was used in
each analysis. Participants were censored at their date of death or,
for those still alive, at the end of follow-up, the date of their last
clinic visit before the termination of the trials. The rate of eGFR
decline over time was estimated in each tertile of 24-h urinary
sodium/creatinine ratio. The difference in eGFR decline between
ARB and non-RAASi–based therapy was estimated by a linear
mixed-effects model with random intercepts and random slopes. For
the purpose of analysis, we combined the subjects assigned to
calcium channel blockers with the placebo group of both trials. To
ascertain the validity of this approach, a sensitivity analysis was
performed excluding the patients assigned to the calcium channel
blocker arm in the IDNT trial. Differences in characteristics of
participating subjects among tertiles of 24-h urinary sodium/
creatinine ratio were determined with one-way analysis of variance
or the Kruskal–Wallis test where appropriate. Relative risk reduc-
tions are described in the text as percentage reductions ((1hazard
ratio) 100). Differences between randomized groups in blood
pressure and albuminuria at month 6 were estimated by analysis of
covariance. All P-values were calculated from two-tailed tests with a
type I error rate of 0.05. Analyses were performed using SAS 9.2 for
Windows (SAS Institute, Cary, NC).
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